Market analysis projects Zeposia trajectory through 2034
A new report from DelveInsight evaluates the commercial outlook and market positioning of Bristol Myers Squibb’s Zeposia for multiple sclerosis and ulcerative colitis treatments.
DelveInsight has released a market assessment evaluating the growth trajectory of Zeposia, an oral S1P receptor modulator developed by Bristol Myers Squibb. The report provides performance insights and revenue forecasts through 2034, focusing on key markets including the United States, EU4, the UK, and Japan.
Zeposia continues to gain market share in the treatment of relapsing forms of multiple sclerosis (MS) and moderately-to-severely active ulcerative colitis (UC). Bristol Myers Squibb reported global sales of $566 million for 2024, marking a 30% year-over-year increase. The drug’s competitive edge is attributed largely to its once-daily oral administration, which serves as an alternative to invasive infusion therapies often required for these chronic conditions.
The assessment highlights Zeposia’s mechanism as a selective S1P modulator, aiming to provide therapeutic efficacy with a manageable safety profile. Recent Phase III DAYBREAK trial results have further supported the drug's long-term utility, showing sustained control of whole brain volume loss in MS patients over a five-year study duration.
Beyond current market performance, the report details regulatory milestones, competitive benchmarking, and future potential in additional indications such as Crohn’s disease. It serves as an analysis of the broader market environment for advanced oral therapies, identifying key growth drivers and barriers that may shape the adoption of Zeposia in the coming years.